Cardiovascular disease is the leading cause of death in postmenopausal women. The menopausal transition is a cardiovascular risk event independent of aging: estrogen withdrawal reduces endothelial function, alters cholesterol profiles, increases arterial stiffness, and promotes visceral fat accumulation and insulin resistance. The protective cardiovascular effect of estrogen in the premenopausal years is one reason women's cardiovascular disease incidence historically lagged behind men's by roughly a decade.

The history of that research is one of the most consequential examples of a study being misread at population scale.

What the WHI Actually Showed

The Women's Health Initiative (WHI) trial found that combined estrogen plus progestogen therapy did not reduce coronary heart disease events and in the first year appeared to increase them. This finding drove a widespread interpretation (communicated to the public and many physicians) that HRT was bad for the heart.

The critical problem was the average age of WHI participants: 63 years, with most women more than 10 years past their final menstrual period.[1] The trial was not studying the effect of starting HRT near menopause. It was studying the effect of introducing estrogen into vessels that had already spent a decade accumulating atherosclerotic plaque without estrogen support.

When the WHI data were re-analysed by age group, a different picture emerged. Women who started HRT in their 50s, within 10 years of menopause, showed reduced coronary heart disease events compared to placebo. Women who started it 20 years after menopause showed increased events.[1] Timing was everything.

The Timing Hypothesis

The timing hypothesis proposes that estrogen is cardioprotective in healthy vascular tissue (where its anti-inflammatory, antioxidant, and endothelial-supporting effects can operate), but that in already-diseased vessels, estrogen may promote plaque instability and inflammatory responses that increase near-term cardiovascular event risk.[2]

Estrogen maintains endothelial function through several mechanisms: stimulating nitric oxide production (which keeps vessels dilated and blood pressure regulated), reducing LDL oxidation, improving HDL cholesterol levels, and reducing arterial wall inflammation.[3] These effects require an intact endothelium. Once significant atherosclerosis has developed, the same mechanisms may operate differently or cause harm.

Starting HRT near menopause, before vascular ageing has progressed, preserves both the cardiovascular benefit of estrogen and the healthy vascular environment in which it acts. Starting it many years later may miss that window.

The ELITE Trial

The first large randomised controlled trial specifically designed to test the timing hypothesis was published in 2016 by the ELITE Research Group.[4] ELITE enrolled 643 healthy postmenopausal women free of clinical cardiovascular disease and randomised them to oral estradiol plus vaginal progesterone or placebo. Participants were stratified by time since menopause: under six years (early group) or over ten years (late group).

In the early group, women assigned to estradiol showed slower progression of atherosclerosis (measured by carotid intima-media thickness, a validated marker of subclinical cardiovascular disease) compared to placebo. In the late group, there was no significant difference between estradiol and placebo.

ELITE provided the first direct experimental evidence that the cardiovascular benefit of HRT is timing-dependent, not absent. It also confirmed that starting HRT late does not confer the same benefit.

Clinical Implications

Taken together, the evidence points to a consistent through-line: timing and route are the two variables that most determine cardiovascular benefit or risk, and both are modifiable at the point of prescribing.

Starting HRT early preserves options. Women who start HRT near the onset of perimenopause are in the window where cardiovascular benefit is most plausible. The case for HRT is strongest before vascular ageing has progressed.

HRT near menopause is not a standalone cardiovascular treatment. The evidence supports it as cardioprotective in healthy women during the transition, not as a therapy for women with established cardiovascular disease or late-onset HRT use.

Route matters. The increased clot and stroke risk associated with oral HRT is relevant to cardiovascular risk assessment. Transdermal estradiol does not carry the same thromboembolic risk as oral estrogen and is preferred for women with cardiovascular risk factors, per current guidelines.[5]

The protective window may close. Guidance from NAMS, NICE, and the British Menopause Society aligns: for healthy women under 60, or within 10 years of menopause, the cardiovascular benefit-risk calculation favours HRT for symptomatic women. For women starting more than 10 years after menopause or over 60 without an established indication, the cardiovascular benefit is less certain.

Vasomotor Symptoms as a Vascular Signal

The cardiovascular consequences of the menopausal transition extend well beyond the years around menopause. Postmenopausal women who had significant vasomotor symptoms during the transition have been found in observational studies to have roughly double the rate of cardiovascular events in subsequent decades compared to women with minimal symptoms.[3] Severe vasomotor symptoms may be a marker of underlying vascular vulnerability.

Prompt treatment of vasomotor symptoms during the transition may therefore carry long-term cardiovascular benefit, not only quality-of-life benefit. Whether treating vasomotor symptoms directly reduces downstream cardiovascular risk, or whether they are purely a marker rather than a cause, is an active area of research, but the signal is consistent enough that frequency and severity of hot flushes are increasingly considered in cardiovascular risk discussions alongside traditional factors.

When to Talk to Your Doctor About Cardiovascular Risk

Not every woman starting HRT needs a cardiology referral, but a cardiovascular-focused conversation with your prescribing clinician is warranted before starting if you have any of the following: a personal or strong family history of heart attack or stroke before age 60, a history of blood clots (deep vein thrombosis or pulmonary embolism), poorly controlled hypertension, type 2 diabetes with vascular complications, or you are more than 10 years past your final menstrual period. In these situations, route of administration (transdermal versus oral), type of progestogen, and baseline cardiovascular risk assessment all become active clinical decisions rather than defaults, and the conversation is worth having before, not after, starting treatment.

References

[1] Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended post-stopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353-1368. See also: The timing hypothesis. https://pubmed.ncbi.nlm.nih.gov/27085786/

[2] Clarkson, T. B., Meléndez, G. C., Appt, S. E. (2013). Timing hypothesis for postmenopausal hormone therapy: Its origin, current status, and future. Menopause, 20(3), 342-353. See also: Cardiovascular health and the menopausal woman. https://pmc.ncbi.nlm.nih.gov/articles/PMC6733383/

[3] Thurston, R. C., Chang, Y., Barinas-Mitchell, E., et al. (2017). Menopausal hot flashes and subclinical cardiovascular disease. Menopause, 24(5), 489-495. See also: Clinical impact of estrogen loss on CVD in menopausal females. https://pmc.ncbi.nlm.nih.gov/articles/PMC7059770/

[4] Hodis, H. N., Mack, W. J., Henderson, V. W., et al. (2016). Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine, 374(13), 1221-1231. https://doi.org/10.1056/NEJMoa1505241

[5] The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The Menopause Society. Menopause, 29(7), 767-794. https://doi.org/10.1097/GME.0000000000002028